Exercise of Warrants

Summary by AI BETAClose X

MedPal AI plc has announced the exercise of warrants for 4,130,833 new ordinary shares at an exercise price of 4 pence per share, raising £165,233.32 for the company. These new shares are expected to be admitted to trading on AIM around September 17, 2026, and will rank equally with existing shares. Following this, the company's total issued share capital will be 783,249,135 ordinary shares.

Disclaimer*

Medpal AI PLC
11 September 2026
 

11 September 2026

MedPal AI plc

("MedPal" or the "Company")

Warrant Exercise

MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-powered, integrated digital health and pharmacy company, announces that the Company has received a notice to exercise warrants over a total of 4,130,833 new ordinary shares of 0.0002 pence each in the Company at an exercise price of 4 pence per share ("Warrant Shares"), raising £165,233.32 for the Company.

ADMISSION AND TOTAL VOTING RIGHTS

Application will be made for the 4,130,833 Warrant Shares to be admitted to trading on AIM which is expected to occur on or around 17 September 2026 ("Admission"). The Warrant Shares will rank pari passu in all respects with the ordinary shares of the Company currently traded on AIM.

Following Admission, the Company's issued share capital will comprise 783,249,135 ordinary shares of 0.0002p each. This number will represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For further information please contact:

Enquiries:

MedPal AI plc

Jason Drummond, Chief Executive Officer

Via Square1 Consulting

Cairn Financial Advisers LLP (Nomad)

Louise O'Driscoll / Jo Turner

+44 (0) 20 7213 0880

OAK Securities (a trading name of Merlin Partners LLP)

Tim Dainton / Calvin Man

+44 (0) 20 3973 3678

Square1 Consulting

David Bick

+44 (0) 20 7929 5599

+44 (0) 7831 381201

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100